Scientists at the Jiangsu Provincial Center for Disease Control and Prevention have found that H7N4 avian influenza is sensitive to gene sequencing-based adamantane and neuraminidase inhibitors after conducting a series of tests on the collected samples of the world’s first human case of the H7N4 strain of avian influenza. The findings, which have been published on the latest issue of Science Bulletin, are believed to be of guiding significance for future clinical treatment.
The world’s first human case of the H7N4 strain of avian influenza was reported in Changzhou city, east China’s Jiangsu province.
A 68-year-old woman had contact with live poultry before she began developing pneumonia-like symptoms on December 25 last year. She was admitted to a hospital January 1 and was discharged after successful treatment January 22.
It was not until February that the virus was identified as being of avian origin, according to a report from the Chinese Center for Disease Control and Prevention.
H7 virus infections in humans are not common and typically cause milder or more moderate illnesses than other avian strains, with symptoms such as conjunctivitis and upper respiratory infections, according to the CDC. The most frequently identified H7 strain in humans is H7N9, with the first human infections reported in China in 2013.
According to the CDC, 1,565 people have been infected with the H7N9 strain since 2013; 39% have died.
(Source: ourjiangsu.com)
